The “Psoriasis Area and Severity Index (PASI)” is commonly used to measure the severity of psoriasis at a specific point in time. This score does not consider the patient history, leaving a possible gap in the satisfaction of patients regarding their care. This cross-sectional study aimed to test if the PeakPASI, the highest PASI ever measured, is a beneficial additional tool to assess the long-term burden, variations in treatments and comorbidities of patients. Psoriasis patients treated at a university hospital between 01/2019 and 07/2020 received a questionnaire. Additional information on clinical scores, therapies, and comorbidities was collected from the patients’ files. The data of 316 patients (53.0±15.5 years, 40.5% women) was analyzed. The mean PASI was 3.8±4.9 and the mean PeakPASI 13.1±9.7. The average number of comorbidities was 2.7±1.8. Around 97.2% of people received a topical therapy and 80.3% received a systemic therapy. More than half the patients (57.0%) received phototherapy. A positive correlation was found between the PeakPASI and the number of topical therapies (rs=0.367, p<.001) and systemic therapies (rs=0.296, p<.001), as well as phototherapy (rs=0.318, p<.001). The prevalence of the five most common comorbidities (smoking, arterial hypertension, drinking alcohol, diabetes, depression) was higher in the group of PeakPASI≥10 compared to PeakPASI<10. People with a PeakPASI≥10 were significantly more likely to receive phototherapy than people with a PeakPASI<10, while no difference was found between people with a PASI<10 and PASI≥10. As a correlation between a higher PeakPASI and different types of therapies as well as comorbidities was found, the PeakPASI is an additional important score for patient care.

The “Psoriasis Area and Severity Index (PASI)” is commonly used to measure the severity of psoriasis at a specific point in time. This score does not consider the patient history, leaving a possible gap in the satisfaction of patients regarding their care. 
This cross-sectional study aimed to test if the PeakPASI, the highest PASI ever measured, is a beneficial additional tool to assess the long-term burden, variations in treatments and comorbidities of patients. Psoriasis patients treated at a university hospital between 01/2019 and 07/2020 received a questionnaire. Additional information on clinical scores, therapies, and comorbidities was collected from the patients’ files. 
The data of 316 patients (53.0±15.5 years, 40.5% women) was analyzed. The mean PASI was 3.8±4.9 and the mean PeakPASI 13.1±9.7. The average number of comorbidities was 2.7±1.8. Around 97.2% of people received a topical therapy and 80.3% received a systemic therapy. More than half the patients (57.0%) received phototherapy. A positive correlation was found between the PeakPASI and the number of topical therapies (rs=0.367, p<.001) and systemic therapies (rs=0.296, p<.001), as well as phototherapy (rs=0.318, p<.001). The prevalence of the five most common comorbidities (smoking, arterial hypertension, drinking alcohol, diabetes, depression) was higher in the group of PeakPASI≥10 compared to PeakPASI<10. People with a PeakPASI≥10 were significantly more likely to receive phototherapy than people with a PeakPASI<10, while no difference was found between people with a PASI<10 and PASI≥10. 
As a correlation between a higher PeakPASI and different types of therapies as well as comorbidities was found, the PeakPASI is an additional important score for patient care.

ESDR119 - PeakPASI Predict: Usefulness of an additional score (highest measured Psoriasis Area and Severity Index) in psoriasis care?

The scientific meeting of the European Society for Dermatological Research (ESDR) is held yearly, usually in September. With an international attendance of more than 1000 skin scientists from around the globe, the four-day event includes short oral presentations from peer-reviewed abstracts, keynote lectures from international experts, sponsored symposia, satellite programs, educational events as well as an important focus on posters, networking and building collaborations amongst scientists. For more information about this year’s meeting visit our website.